Phaseline

Companies › Chengdu Zenitar Biomedical Technology

Chengdu Zenitar Biomedical Technology: clinical trials, targets and expected readouts

4 active drug programs in 11 registered trials: 6 Phase 2, 3 Phase 1, 2 Phase 3; Oncology, Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Purinostat Mesylate for Injection
Class Ia and IIb HDAC selective inhibitor
HDAC (class I/II)Phase 3Recurrent and Refractory Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma,DLBCL; Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Relapsed or Refractory Multiple Myeloma (RRMM) …Dec 2026
Flonoltinib Maleate
JAK1/JAK2 inhibitor
JAK1, JAK2Phase 3MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV)May 2027
ZL-82–Phase 2Atopic DermatitisDec 2027
ZL-65 tablet–Phase 1Healthy Participants StudyJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06484829Purinostat Mesylate for InjectionPhase 1Relapsed or Refractory Multiple Myeloma (RRMM)OncologyFeb 2026
NCT06431243Purinostat Mesylate for InjectionPhase 1Advanced Solid TumorOncologyMay 2026
NCT05563844Purinostat Mesylate for InjectionPhase 2Diffuse Large B Cell Lymphoma,DLBCLOncologyDec 2026
NCT06485219Purinostat Mesylate for InjectionPhase 2Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)OncologyDec 2026
NCT06457425Flonoltinib MaleatePhase 2MF,PMF,PPV-MF,PET-MFOtherMay 2027
NCT07232290Flonoltinib MaleatePhase 2Polycythemia Vera (PV)OncologyJul 2027
NCT07757152ZL-65 tabletPhase 1Healthy Participants StudyOtherJul 2027
NCT07317700Flonoltinib MaleatePhase 3MFOncologyDec 2027
NCT07443306Flonoltinib MaleatePhase 2MFOncologyDec 2027
NCT07193589ZL-82Phase 2Atopic DermatitisImmunologyDec 2027
NCT07011056Purinostat Mesylate for InjectionPhase 3Recurrent and Refractory Diffuse Large B-cell LymphomaOncologyJun 2029

Targets

JAK1 (1) JAK2 (1) HDAC (class I/II) (1)

Companies with the same targets

Incyte AbbVie Pfizer Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Alfasigma Takeda Eli Lilly LEO Pharma GSK

Companies built like this

Dizal Pharmaceuticals Shanghai Kechow Pharma J-Pharma Beijing InnoCare Pharma Tech InventisBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.